Mesa Laboratories (MLAB)
(Delayed Data from NSDQ)
$126.18 USD
+3.70 (3.02%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $125.71 -0.47 (-0.37%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$126.18 USD
+3.70 (3.02%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $125.71 -0.47 (-0.37%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Zacks News
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Surging Earnings Estimates Signal Upside for Mesa Labs (MLAB) Stock
by Zacks Equity Research
Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Mesa Labs (MLAB) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for August 26th
by Zacks Equity Research
QFIN, GHM, CRNC, SUPV and MLAB have been added to the Zacks Rank #1 (Strong Buy) List on August 26, 2024.
DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
DarioHealth (DRIO) delivered earnings and revenue surprises of 66.10% and 3.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 18.18% and 1.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Best Value Stocks to Buy for April 8th
by Zacks Equity Research
SM and MLAB made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 8, 2023.
Mesa Labs (MLAB) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -0.98% and 2.60%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 3.12% and 11.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Penumbra and Mesa Labs have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Penumbra and Mesa Labs are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Mesa Labs (MLAB)
by Kevin Cook
Mesa diagnostics gains importance among big pharma so we want to watch this dip
Mesa Labs (MLAB) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 5.99% and 2.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -2.02% and 3.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (RWLK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of 12.50% and 38.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
RxSight, Inc. (RXST) delivered earnings and revenue surprises of 19.23% and 7.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 27.16% and 10.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28, Inc. (FNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -10% and 3.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -209.09% and 63.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Mesa Labs (MLAB) closed the most recent trading day at $171.42, moving -1.89% from the previous trading session.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Is Mesa Labs (MLAB) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Mesa Labs (MLAB) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Mesa Labs (MLAB) Tops Q3 Earnings Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 11.90% and 5.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?
by Zacks Equity Research
Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.
Mesa Labs (MLAB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Mesa Labs (MLAB) closed at $193.27 in the latest trading session, marking a +0.56% move from the prior day.